Progresses in Nano-Enabled Platforms for the Treatment of Vaginal Disorders.
Nanocarriers
non invasive drug
targeted drug delivery
therapeutic efficacy
vaginal disorders
vaginal drug delivery
Journal
Recent patents on nanotechnology
ISSN: 2212-4020
Titre abrégé: Recent Pat Nanotechnol
Pays: United Arab Emirates
ID NLM: 101291922
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
02
2022
revised:
05
05
2022
accepted:
12
05
2022
pubmed:
29
6
2022
medline:
28
3
2023
entrez:
28
6
2022
Statut:
ppublish
Résumé
The most common vaginal disorders are within the uterus. According to the latest statistics, vaginal disorders occur in 50% to 60% of females. Although curative treatments rely on surgical therapy, still first-line treatment is a non invasive drug. Conventional therapies are available in the oral and parenteral route, leading to nonspecific targeting, which can cause dose-related side effects. Vaginal disorders are localized uterine disorders in which intrauterine delivery via the vaginal site is deemed the preferable route to mitigate clinical drug delivery limitations. This study emphasizes the progress of site-specific and controlled delivery of therapeutics in the treatment of vaginal disorders and systemic adverse effects as well as the therapeutic efficacy. Related research reports and patents associated with topics are collected, utilized, and summarized the key findings. The comprehensive literature study and patents like (US 9393216 B2), (JP6672370B2), and (WO2018041268A1) indicated that nanocarriers are effective above traditional treatments and have some significant efficacy with novelty. Nowadays, site-specific and controlled delivery of therapeutics for the treatment of vaginal disorders is essential to prevent systemic adverse effects and therapeutic efficacy would be more effective. Nanocarriers have therefore been used to bypass the problems associated with traditional delivery systems for the vaginal disorder.
Sections du résumé
BACKGROUND
BACKGROUND
The most common vaginal disorders are within the uterus. According to the latest statistics, vaginal disorders occur in 50% to 60% of females. Although curative treatments rely on surgical therapy, still first-line treatment is a non invasive drug. Conventional therapies are available in the oral and parenteral route, leading to nonspecific targeting, which can cause dose-related side effects. Vaginal disorders are localized uterine disorders in which intrauterine delivery via the vaginal site is deemed the preferable route to mitigate clinical drug delivery limitations.
OBJECTIVE
OBJECTIVE
This study emphasizes the progress of site-specific and controlled delivery of therapeutics in the treatment of vaginal disorders and systemic adverse effects as well as the therapeutic efficacy.
METHODS
METHODS
Related research reports and patents associated with topics are collected, utilized, and summarized the key findings.
RESULTS
RESULTS
The comprehensive literature study and patents like (US 9393216 B2), (JP6672370B2), and (WO2018041268A1) indicated that nanocarriers are effective above traditional treatments and have some significant efficacy with novelty.
CONCLUSION
CONCLUSIONS
Nowadays, site-specific and controlled delivery of therapeutics for the treatment of vaginal disorders is essential to prevent systemic adverse effects and therapeutic efficacy would be more effective. Nanocarriers have therefore been used to bypass the problems associated with traditional delivery systems for the vaginal disorder.
Identifiants
pubmed: 35762539
pii: NANOTEC-EPUB-124854
doi: 10.2174/1872210516666220628150447
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
208-227Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.